Helix BioPharma Corp. announces the signing of a non-binding letter of intent with ProMab Biotechnologies to develop cell based therapies.
Helix BioPharma Corp., a clinical stage immuno-oncology company developing drug candidates for the prevention and treatment of cancer, announced that it has signed a non-binding letter of intent (LOI) with ProMab Biotechnologies to develop cell based therapies.
The LOI calls for both companies to complete a due diligence and establish a collaboration to develop chimeric antigen receptor T cell therapy (CAR-T) for hematological malignances and solid tumors. The collaboration will seek to exploit Helix novel single-domain antibodies based CAR-T and ProMab’s proprietary vector designs, antibodies library and cell based production know-how.
“We are delighted to work with ProMab. I look forward to establish this collaboration and further our CAR-T program,” said Dr. Sven Rohmann, Helix’s chief executive officer.
Helix BioPharma Corp. specializes in the field of cancer therapy. The company is actively developing products for the prevention and treatment of cancer based on its proprietary technologies. Helix’s product development initiatives include its novel L-DOS47 new drug candidate.
Filed Under: Drug Discovery